The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas

Current Hematologic Malignancy Reports

Volumn 6, Issue 1, 2011, Pages 67-72

  Horwitz, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Belinostat; CTCL; Cutaneous T cell lymphoma; Depsipeptide; Histone deacetylase inhibitors; Novel therapies; Panobinostat; Peripheral T cell lymphoma; PTCL; Romidepsin; SAHA; T cell lymphoma; Vorinostat

Indexed keywords

ARGININE BUTYRATE; ARGININE DERIVATIVE; BELINOSTAT; BEXAROTENE; BORTEZOMIB; DACLIZUMAB; GANCICLOVIR; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; PANOBINOSTAT; ROMIDEPSIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANOREXIA; ARTICLE; BODY WEIGHT; CANCER SURVIVAL; CARDIOTOXICITY; CONSTIPATION; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; HODGKIN DISEASE; HUMAN; LUNG EMBOLISM; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; SIDE EFFECT; SINGLE DRUG DOSE; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 79551490303     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0067-5     Document Type: Article

References (30)

1. C Gisselbrecht P Gaulard E Lepage, et al. 1998 Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA) Blood 92 76 82 1:CAS:528:DyaK1cXktleruro%3D 9639502
2. OA O'Connor S Horwitz P Hamlin, et al. 2009 Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies J Clin Oncol 27 4357 64 10.1200/JCO.2008.20.8470 19652067
3. A Jaccard B Petit S Girault, et al. 2009 L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature Ann Oncol 20 110 6 1:STN:280:DC%2BD1M%2Fns12ktA%3D%3D 10.1093/annonc/mdn542 18701429
4. PA Marks VM Richon RA Rifkind 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J Natl Cancer Inst 92 1210 6 1:CAS:528:DC%2BD3cXlvFyhsb8%3D 10.1093/jnci/92.15.1210 10922406
5. KN Bhalla 2005 Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies J Clin Oncol 23 3971 399 1:CAS:528:DC%2BD2MXmtVahtLg%3D 10.1200/JCO.2005.16.600 15897549 (Pubitemid 46218700)
6. R Furumai A Matsuyama N Kobashi, et al. 2002 FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res 62 4916 21 1:CAS:528:DC%2BD38Xmslylu78%3D 12208741
7. RL Piekarz R Robey V Sandor, et al. 2001 Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report Blood 98 2865 8 1:CAS:528: DC%2BD3MXotVegt74%3D 10.1182/blood.V98.9.2865 11675364
8. SP Perrine O Hermine T Small, et al. 2007 A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies Blood 109 2571 8 1:CAS:528:DC%2BD2sXnslygtr4%3D 10.1182/blood-2006-01-024703 17119113 (Pubitemid 46425904)
9. OA O'Connor ML Heaney L Schwartz, et al. 2006 Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 24 166 73 10.1200/JCO.2005.01.9679 16330674 (Pubitemid 46630509)
10. M Duvic R Talpur X Ni, et al. 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31 9 1:CAS:528:DC%2BD2sXivVyrt7g%3D 10.1182/blood-2006-06- 025999 16960145 (Pubitemid 46053039)
11. EA Olsen YH Kim TM Kuzel, et al. 2007 Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J Clin Oncol 25 3109 15 1:CAS:528:DC%2BD2sXptlGrtrs%3D 10.1200/JCO.2006.10.2434 17577020 (Pubitemid 47218059)
12. RL Piekarz R Frye M Turner, et al. 2009 Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol 27 5410 7 1:CAS:528:DC%2BD1MXhsFKkt7vO 10.1200/JCO.2008.21.6150 19826128
13. SJ Whittaker MF Demierre EJ Kim, et al. 2010 Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma J Clin Oncol 28 4485 91 1:CAS:528:DC%2BC3cXhsVejt7zL 10.1200/JCO.2010.28.9066 20697094 This article describes the largest experience with romidepsin in CTCL and gives an excellent description of response criteria for CTCL studies.
14. R Piekarz J Wright R Frye 2009 Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL) [abstract] Blood 114 1657a
15. • Coiffier B, Horwitz S, Whittaker S: Romidepsin experience in 317 patients with T-cell lymphomas [abstract]. Proceedings of the European Hematology Association 2010:0572a. This abstract describes largest experience of a single drug in T-cell lymphomas and highlights important potential differences in toxicities between CTCL and PTCL.
16. D Ritchie R Piekarz P Blombery, et al. 2009 Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report Haematologica 94 1618 22 1:CAS:528:DC%2BC3cXjsV2mtQ%3D%3D 10.3324/haematol.2009. 008607 19608677 This article describes immunosuppressive properties of HDACi that may be greater than previously appreciated
17. MH Shah P Binkley K Chan, et al. 2006 Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors Clin Cancer Res 12 3997 4003 1:CAS:528:DC%2BD28XmsValurw%3D 10.1158/1078-0432.CCR-05-2689 16818698 (Pubitemid 44078086)
18. RL Piekarz AR Frye JJ Wright, et al. 2006 Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma Clin Cancer Res 12 3762 73 1:CAS:528:DC%2BD28XlvVSltr8%3D 10.1158/1078-0432.CCR-05- 2095 16778104 (Pubitemid 44000258)
19. PN Munster EH Rubin S Van Belle, et al. 2009 A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer Clin Cancer Res 15 7077 84 1:CAS:528:DC%2BD1MXhtl2ktLfI 10.1158/1078-0432.CCR-09-1214 19887475
20. B Pohlman R Advani M Duvic 2009 Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract] Blood 114 920a
21. M Prince D George A Patnaik 2007 Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin's lymphoma [abstract] J Clin Oncol 25 3500a
22. M Duvic JC Becker S Dalle 1005 Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL) [abstract] Blood 2008 112
23. R Dummer K Hymes W Sterry 2009 Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: a phase I study [abstract] J Clin Oncol 27 8572
24. J Chen M Zhang W Ju TA Waldmann 2009 Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25 Blood 113 1287 93 1:CAS:528:DC%2BD1MXitV2rurY%3D 10.1182/blood-2008-04-149658 18948574
25. U Heider J Rademacher B Lamottke, et al. 2009 Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma Eur J Haematol 82 440 9 1:CAS:528: DC%2BD1MXmtVyls70%3D 10.1111/j.1600-0609.2009.01239.x 19220424
26. QL Zhang L Wang YW Zhang, et al. 2009 The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis Leukemia 23 1507 14 1:CAS:528:DC%2BD1MXpvF2kurk%3D 10.1038/leu.2009.41 19282831
27. A Badros AM Burger S Philip, et al. 2009 Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin Cancer Res 15 5250 7 1:CAS:528:DC%2BD1MXpvFeit7Y%3D 10.1158/1078-0432.CCR-08- 2850 19671864
28. SJ Harrison H Quack K Yuen 2008 High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial [abstract] Blood 112 3698
29. G Dueck N Chua A Prasad, et al. 2010 Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma Cancer 116 4541 8 1:CAS:528:DC%2BC3cXht1KnsLrJ 10.1002/cncr.25377 20572046
30. Siegel DS, Weber, D. M, Mitsiades,C. S. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study [abstract]. J Clin Oncol 2009, 27:abstract 8586.